Sampled Announces Selection as a Contractor Supporting the Genomic Characterization Center by The National Cancer Institute Effective 01/13/2025

PISCATAWAY, N.J., March 26, 2025 /PRNewswire/ -- Sampled, an integrated analytical biorepository and multiomics company, is proud to announce its selection as a Genomic Characterization Center for the Genome Characterization program of the National Cancer Institute (NCI), part of the National Institutes of Health. This prestigious Indefinite Delivery, Indefinite Quantity (IDIQ) contract has a funding ceiling of $150 million, positioning Sampled as a key contributor to supporting the advancement of cutting-edge cancer research and genomic discovery.

Under the award, Sampled will participate in all four contract pools, leveraging its state-of-the-art technologies and expertise to deliver comprehensive genomic solutions:

Pool 1 – DNA Sequencing: Whole Genome Sequencing and Whole Exome Sequencing using DNA extracted from FFPE or fresh frozen samples to support researchers comprehensive understanding of cancer biology by identifying mutations, structural variations, and genetic abnormalities that drive tumor progression critical for advancing precision oncology, uncovering novel therapeutic targets, and supporting large-scale cancer genomic studies.

Pool 2 – RNA Sequencing: RNAseq and microRNAseq using RNA extracted from FFPE or fresh frozen samples for transcriptomic analysis which will support researchers to analyze gene expression and regulatory pathways, revealing how genetic changes affect tumor development and behavior, essential for to identify biomarkers, study tumor microenvironment interactions, and potentially monitor responses to cancer therapies.

Pool 3 – Epigenome Characterization: Methylation and Chromatin Accessibility Characterization with array and sequencing based assays using DNA extracted from FFPE or fresh frozen samples to support NCI researchers to investigate critical changes, such as methylation patterns and chromatin remodeling, that drive cancer progression and therapeutic resistance.

Pool 4 – Single Cell/Spatial Characterization: Single-cell RNA, ATAC-seq, Spatial, and In Situ Analyses from FFPE or fresh frozen samples allowing a detailed understanding of tumor heterogeneity and the tumor microenvironment by analyzing individual cells and their interactions, for studying treatment resistance, advancing immunotherapy, and personalizing cancer care.

"Being part of the NCI Genome Characterization contract is a testament to Sampled's unwavering commitment to delivering innovative and reliable solutions for cancer research," said Greg Morrissey, Sr Director Government / Public Sector at Sampled. "Our participation across all four contract pools underscores our diverse capabilities in supporting the scientific community to uncover the complexities of cancer and drive precision medicine forward."

"Sampled's selection for this contract is a significant milestone in our mission to support cancer researchers with cutting-edge multiomics tools," said Shareef Nahas, Chief Scientific Officer of Sampled. "Our team is deeply committed to advancing human health and medicine. This partnership with the NCI allows us to contribute directly to advancing oncology research, accelerating the discovery of novel cancer therapies, and improving patient outcomes through comprehensive genomic and molecular insights."  

As a trusted partner to the NCI and the broader research community, Sampled's contributions will enable groundbreaking discoveries in cancer genomics and epigenetics. The company's integrated approach, combining cutting-edge technologies, robust infrastructure, and unparalleled expertise, ensures that researchers have access to the highest quality data and insights.

About Sampled:

Sampled is a fully integrated laboratory and biorepository with industry-leading storage, sample management, multiomics, cellular services, and custom clinical kitting. Founded in 1999 as RUCDR Infinite Biologics at Rutgers University, Sampled operates laboratories in the US and UK and is CAP accredited and CLIA licensed. Sampled is committed to providing the highest quality sample processing and analysis services that enable researchers to make new discoveries and advance human health. When combined with state-of-the-art biobanking facilities, these capabilities provide comprehensive scientific solutions that speed time to quality data.

Media Contact:
Caroline Mitchell
Director, Content & Creative Strategy
[email protected]
+1 732-273-0699

SOURCE Sampled